on one hand, this can't be good. losing a lot of credibility and revenue by detaching from jnj.
but given is making it sound as if they wanted this, so they can begin to market this on their own. i can't imagine why a small company like given would try marketing on their own, if they have backing from jnj. i am not long or short. and i will not buy until i see some results from this disassociation.
I remember a small company called Closure Medical years ago that had an exclusive deal with JNJ, and it hurt the growth of Closure Medical a lot. Closure Medical could not grow unless JNJ sales guys pushed it. Closure Medical was eventually bought for small money. I imagine JNJ wanted some kind of exclusive deal with GIVN for the Pillcam, and GIVN refused such a bad deal. That is my take on what probably happened. If it was an exclusive, GIVN was smart to get away from JNJ.
i don't know that it was so smart. jnj is powerful enough to prevent givn from doing anything in the us. i think they should have gotten into some kind of agreement, but pride and euphoria got the better of them. the product is good, but for a public company that's not enough. look at fonar battle with ge for years.
so all in all i think it was a mistake, and i think givn is going back to teens,and stays there for a while.
It is very clear - the idea of Eso Pill was failed, Docs and patients do not love it and prefer the 2 minutes simple procedure by Gastroscope acompanied by slight sedataion. I am convinced that J&J got to this conclusion. Another speculation is that Givn might be bought and they didn't want a a "tail". However Olympus case will certainly comes to an end sooner and it is clearly more important to investors.